Earlier last week, another city in the state of Michigan passed a measure that called for the decriminalization of psychedelics, including ayahuasca and psilocybin. The measure doesn’t meet activists’ expectations, however, because it doesn’t change any enforcement practices in the city. Instead, the initiative stipulates that the city commission and mayor support federal, state and local legislative efforts to decriminalize entheogenic fungi and plants as well as plant-based compounds that are classified under the Controlled Substances Act.
The measure, which the city commission of Grand Rapids approved in a 5 to 2 vote, states that individuals who seek to improve their well-being and health through the use of entheogenic fungi and plants should have the freedom to do so without risk of prosecution or arrest. It further notes that the enforcement of laws that regulate the use and possession of entheogenic fungi and plants hasn’t been a high priority for the city of Grand Rapids.
The move comes as state and local legislators across Michigan pursue other psychedelic policy changes. For example, the city council of Ann Arbor, Michigan, decided to make the enforcement of laws that prohibit the use of psychedelics such as DMT, ayahuasca and psilocybin among the city’s lowest priorities. After lawmakers in Ann Arbor approved the decriminalization measure in 2020, the county prosecutor in Washtenaw announced that his office wouldn’t be pursuing charges involving the possession of entheogenic fungi and plants. Furthermore, legislators recently declared September to be the Entheogenic Fungi and Plants Awareness month.
Psychedelics policy reforms are also advancing in other states in the country. In California, a measure to legalize psychedelics that had advanced through a pair of assembly committees and the senate was recently withdrawn by its sponsor so that it could garner more support among legislators. Activists in the state have also began gathering signatures for a measure that would legalize magic mushrooms in the state. In addition to this, Santa Cruz and Oakland, both cities in California, have enacted psychedelics decriminalization measures.
Last week, a top Democrat in the Florida Senate filed a legislation that would require the state to study the medical benefits of psychedelic substances such as MDMA and psilocybin. In 2020, voters in the state of Oregon also approved two measures that decriminalized the possession of all drugs and legalized psilocybin therapy. Additionally, voters in Washington D.C. passed a ballot initiative in 2020 that deprioritized the enforcement of laws that criminalize psychedelic substances.
California seems to be taking solid steps to remove psychedelics from the list of prohibited substances. It is therefore no wonder that cutting-edge psychedelic research is being undertaken by companies such as Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF), headquartered in California.
NOTE TO INVESTORS: The latest news and updates relating to Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) available in the company’s newsroom at https://ibn.fm/TRYPF
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)
For more information please visit https://www.psychedelicnewswire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.psychedelicnewswire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.psychedelicnewswire.com
415.949.5050 Office
Editor@PsychedelicWire.com
PsychedelicNewsWire is part of the InvestorBrandNetwork.
